TCRX
Tscan Therapeutics Inc

733
Loading...
Loading...
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
194

Frequently Asked Questions

What is Market Cap of Tscan Therapeutics Inc?
What is the 52-week high for Tscan Therapeutics Inc?
What is the 52-week low for Tscan Therapeutics Inc?
What is Tscan Therapeutics Inc stock price today?
What was Tscan Therapeutics Inc stock price yesterday?
What is the PE ratio of Tscan Therapeutics Inc?
What is the Price-to-Book ratio of Tscan Therapeutics Inc?
What is the 50-day moving average of Tscan Therapeutics Inc?
How many employess does Tscan Therapeutics Inc has?

Latest TCRX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.